Introduction {#Sec1}
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On December 31, 2019, the first cases of pneumonia of a new type of virus in the family Coronaviridae, named SARS-CoV-2, were reported in Wuhan. So far, more than 10.000.000 cases have been detected worldwide \[[@CR1]\]**.** The first patient infected with SARS-CoV-2 virus in Spain was identified in January 2020, being Madrid the city with the greatest impact, with 72.000 confirmed cases and more than 8300 deceased by May 2020 \[[@CR2]\].

Individuals with rheumatic and musculoskeletal diseases (RMDs) and immunosuppressive therapies may require special consideration because receiving immunosuppressant therapies made them more susceptible to viral and bacterial infections. However, to date, it has not shown a higher incidence of Coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases compared to the general population \[[@CR3]\], even if receiving biologic disease-modifying antirheumatic drug (b-DMARD) therapy \[[@CR4], [@CR5]\]. In addition, a preliminary survey study showed that patients treated with DMARDs and infected with COVID-19 did not develop life-threatening complications due to their underlying medication \[[@CR6]\].

Multiple guidelines from different scientific societies have been published with recommendations for COVID-19 in rheumatic patients. It seems that the risk of severe outcomes in patients with rheumatic diseases and COVID-19, is tied to age and comorbidities as in the general population \[[@CR7], [@CR8]\]. However, as comorbidities occur more frequently in patients with rheumatic disease as a result of the baseline disease or as a complication of treatment, there is a major need to determine which therapies or baseline factors may increase the vulnerability to infection and may predict poorer outcomes.

Treatments commonly used in patients with rheumatic disease have been shown useful to treat COVID-19. For example, as interleukin (IL)-6 is a cytokine highly expressed in severe forms of COVID-19 associated to the cytokine storm \[[@CR9]\], IL-6 inhibitors are currently being used in the treatment of severe COVID-19. It is not clear if IL-6 inhibitors already prescribed in rheumatic patients may have a protective effect.

The aim of our study was to describe epidemiological and clinical characteristics of patients with rheumatic and musculoskeletal diseases (RMDs), treated with immunosuppressive therapies presenting COVID-19 in a reference hospital in Spain, and to explore baseline variables, included diagnosis and baseline therapy, associated with a more severe infection requiring hospitalization.

Patients and methods {#Sec2}
====================

**Patients** We conducted a retrospective observational study including patients with any rheumatologic autoimmune or inflammatory diseases evaluated in our rheumatology department and who were infected with SARS-CoV2 between March 4 and April 24, 2020.

In our department, we maintain an updated database of patients with any rheumatologic autoimmune disease, including systemic lupus erythematosus (SLE), Sjögren´s syndrome (SS), systemic sclerosis (SSc), polymyalgia rheumatica (PMR), giant cell arteritis (GCA) and other systemic vasculitis and inflammatory myopathies. We identified SARS-CoV-2 positive by polymerase chain reaction (PCR) performed at our center with our database of rheumatology patients evaluated at our clinic and with an updated registry of patients on active biological therapy from January 2020, mostly patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) who were receiving any of the following treatments: anti-TNF alpha drugs (etanercept, adalimumab, infliximab, golimumab and certolizumab), IL-1 inhibitors (anakinra), IL-6 inhibitors (tocilizumab), IL 12/23 inhibitors (ustekinumab), IL-17 inhibitors (secukinumab), CTLA4-Ig (abatacept), JAK inhibitors (tofacitinib, baricitinib and ruxolitinib). Additional RMDs patients were identified when they contacted our clinic to inform us about a positive COVID-19 infection.

A diagnosis of SARS-CoV2 was considered if the patient had a positive polymerase chain reaction (PCR) test on respiratory samples during the study time frame or if there were high suspicions of infection \[Compatible respiratory symptoms (dyspnea, cough, anosmia, ageusia, low O~2~ saturations) with radiographic images of pneumonic infiltrates with hospitalization and/or therapy initiation specific for COVID-19\].

We collected the following data from the electronic health records: demographic characteristics, comorbidities, and clinical characteristics of the infection, laboratory test data, and outcome (dead, hospital admission). The "standard treatment" for COVID-19 offered at our institution included hydroxychloroquine and/or lopinavir--ritonavir and/or azithromycin, and for patients requiring hospitalization oxygen therapy, glucocorticoids, remdesivir, anti-interleukine-6 (tocilizumab), and anti-interleukine-1 (anakinra) may be also added for treatment intensification.

Baseline treatment-related data were extracted from the electronic health records for type of DMARD prescribed (i.e., methotrexate, hydroxychloroquine, leflunomide, sulfasalazine), biologic treatment, and prednisone use and dose in milligrams. Time from symptom onset to PCR testing was also calculated. Any radiographic evidence of pneumonia at the medical center was also recorded.

**Statistical analysis** The results of descriptive analyses were presented using frequencies and percentages for qualitative variables and as median or mean values for continuous variables. The patients were classified in two groups according to the severity of COVID-19 infection requiring or not requiring hospitalization. Between-group comparisons were made using Student's *t* test to analyze differences between means; chi-square tests were used for comparisons between proportions. Nonparametric tests (i.e., Kruskal--Wallis) were used for data that did not meet the assumptions of a normal distribution. Normality in distribution was tested by graphical and numerical methods. A histogram plot and Skewness/Kurtosis tests were computed for each variable.

We used a bivariate logistic regression model to assess factors associated with a more severe infection requiring hospitalization. Age higher than 70, being male, having RA, SpA or SLE in comparison with other rheumatic diagnosis, comorbidities, and baseline therapy were evaluated for possible association with a more severe infection requiring hospitalization. Any factor with a *p* value \< 0.15 in the bivariate analysis was included in the multivariate analysis. The multivariable logistic regression model first included all variables that were significant; backward elimination was then used to select the final model.

All statistical tests were two-sided; *p* values \< 0.05 were considered to indicate a statistically significant result. STATA 12.0® for Mac (StataCorp LP, College Station, TX) software was used for all analyses.

Ethics and institutional review board approval {#Sec3}
----------------------------------------------

This study was performed in accordance with the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration of 1975, as revised in 2013. All data were anonymised, and the study was approved by the Ethics Committee of Hospital General Universitario Gregorio Marañón (April 27th, ref Nº CEIm: 12/2020).

Results {#Sec4}
=======

We identified 62 patients with COVID-19 between March 4 and April 24, 2020 with a follow-up in our department for a rheumatologic autoimmune or inflammatory disease.

Forty-two patients (68%) were hospitalized and 20 (32%) were followed up at in-home isolation, out of the total of 62 patients, 51 had a positive PCR. Patient characteristics are presented in Table [1](#Tab1){ref-type="table"}. The patient's mean age was 60.9 years, 42% were men. The most common rheumatologic diagnosis was RA (32%) followed by SpA (26%). The most common comorbidities were cardiovascular disease (52%), and hypertension (45%).Table 1Comparison of demographic, baseline clinical characteristics and outcomes of patients with different rheumatic conditions infected with COVID-19 by hospitalizationTotal\
*N* = 62Non-hospitalized\
*N* = 20 (32%)Hospitalized\
*N* = 42 (68%)*p*Age, mean (SD)60.9 (13.9)56.4 (10.8)63.0 (14.9)0.08Patients ≥ 70 years, number (%)18 (29%)2 (10%)16 (38%)0.02Male, number (%)26 (42%)4 (20%)22 (52%)0.01Rheumatic diagnosis Rheumatoid Arthritis20 (32%)5 (25%)15 (36%)0.60 SpA/psoriatic arthritis16 (26%)5 (25%)11 (26%) Other inflammatory4 (6%)1 (5%)3 (7%) SLE9 (15%)3 (15%)6 (14%) Other CTD13 (21%)6 (30%)7 (17%) Disease duration, years, mean (SD)11.1 (8.5)10.6 (8.7)11.3 (8.5)0.74Comorbidities Obesity20 (33%)4 (20%)16 (40%)0.12 Diabetes mellitus12 (20%)0 (0%)12 (30%)0.006 Hypertension27 (45%)4 (20%)23 (57%)0.006 Cardiovascular disease31 (52%)6 (30%)25 (62%)0.01 Lung disease14 (23%)1 (5%)13 (32%)0.01Baseline therapy Glucocorticoids, *n* (%)30 (48%)5 (25%)25 (59%)0.01 Dose ≥ 5 mg, *n* (%)27 (44%)4 (20%)23 (55%)0.01Non-biologics DMARDS Hydroxychloroquine9 (14%)3 (15%)6 (14%)0.94 Methotrexate12 (19%)2 (10%)10 (24%)0.19 Leflunomide3 (5%)0 (0%)3 (7%)0.22Biologics Anti-TNF12 (19%)5 (25%)7 (17%)0.43 Tocilizumab4 (6%)2 (10%)2 (5%)0.43 Tofacitinib2 (3%)1 (5%)1 (2%)0.58 Positive PCR for SARS-CoV2 (respiratory samples)51 (82%)15 (75%)36 (86%)0.30 Health Care Personnel7 (13%)6 (33%)1 (3%)0.002Clinical features C-reactive protein (mg/dL), median (IQR)3.6 (1.7--10.8)1.5 (1.4--2.1)4.4 (1.8--10.9)0.09 Lymphocytes (/mm^3^), median (IQR)1100 (700--1700)1850 (1400--1900)1050 (700--1500)0.05 Pneumonia by chest X-ray36 (64%)1 (6%)35 (87%) \< 0.001COVID-19 therapy, number (%) Hydroxychloroquine40 (64%)3 (15%)37 (88%)0.001 Lopinavir/ritonavir36 (58%)3 (15%)33 (79%)0.001Glucocorticoids Azithromycin9 (15%)0 (0%)9 (21%)0.02 Tocilizumab5 (8%)0 (0%)5 (12%)0.10Outcome, number (%) Death10 (16%)1 (5%)9 (21%)0.14*CTD* connective tissue diseases, *DMARDs* disease-modifying antirheumatic drugs, *IQR* Interquartile range, *PCR* polymerase chain reaction, *SLE* systemic lupus erythematosus, *SpA* spondyloarthropathies, *SD* standard deviation, *TNF* tumor necrosis factor

Male gender, cardiovascular disease, hypertension, and diabetes were associated with a more severe infection requiring hospital admission (*p* ≤ 0.05). No statistically significant differences were observed between the two groups (hospitalized versus non-hospitalized) with regard to rheumatologic diagnosis and use of immunosuppressive drugs except for glucocorticoids that were more frequently used in patients requiring hospitalization. Around one-third of patients not requiring hospitalization were health care personnel. Eighty-seven percent (87%) of hospitalized patients have radiograph findings compatible with pneumonia and received a more intensive treatment in line with higher severity. Azithromycin, hydroxychloroquine, lopinavir/ritonavir and tocilizumab were prescribed either in monotherapy or in combination and tocilizumab was used in 5 (12%) hospitalized patients. No statistical differences were observed between the two groups in terms of mortality; however, death clearly tended to be more frequent in the hospitalized group (21% versus 5%, *p* = 0.14).

A total of 10 patients died (16%), most of them (9 patients) in the hospitalized group: 3 with RA, 2 with LES, 1 with SpA and 4 with other rheumatic diseases. Patients who died were older (72.8 years old versus 59.9, *p* \< 0.001), most of them were men (70%), and had more comorbidities, mainly DM (60%) and HTA (80%).

Results from the multivariate analyses (Table [2](#Tab2){ref-type="table"}) revealed an association between male sex, preexisting lung disease and treatment with glucocorticoids (≥ 5 mg per day) with a more severe infection requiring hospitalization.Table 2Associations between baseline characteristics and more severe infection requiring hospitalization; results of bivariate and multivariate **l**ogistic regression analyses (*n* = 62)VariablesBivariate analysesMultivariate analysesOR (95% CI)*P* valuesOR (95% CI)*P* valuesAge ≥ 70 years5.50 (1.13--27.10)0.0352.6 (0.42--16.21)0.303Men (Women = reference)4.40 (1.25--15.39)0.0207.4 (1.58--34.90)0.011RA1.67 (0.50--5.49)0.401----SPA1.06 (0.31--3.62)0.920----SLE0.94 (0.21--4.24)0.941----Obesity2.66 (0.75--9.44)0.1290.64 (0.09--4.48)0.656Hypertension5.41 (1.53--19.12)0.0096.21 (0.58--66.62)0.579Cardiovascular disease3.89 (1.23--12.29)0.0210.73 (0.12--4.54)0.738Lung disease9.14 (1.10--75.98)0.0408.93 (1.25--63.48)0.029Glucocorticoids dose ≥5mg/day4.84 (1.38--16.95)0.0145.00 (1.08--23.15)0.040*CI* confidence interval, *OR* odds ratio, *RA* rheumatoid arthritis,*SLE* systemic lupus erythematosus, *SpA* spondyloarthropathies

Discussion {#Sec5}
==========

In the present study, we report how patients with inflammatory and autoimmune rheumatic diseases from our center were affected by COVID-19 infection. Our results support that male sex, preexisting lung disease and baseline treatment with glucocorticoids (\> 5 mg/day) are associated with higher odds of a more severe infection requiring COVID-19 hospitalization. We did not find association between hospitalization and specific rheumatic diagnosis or baseline therapy. The rate of hospitalization was high in our cohort (68%), reflecting identification by PCR positivity and probably underestimating less severe cases in patients who did not reach medical care.

Our results are in line with previously described in the literature, alerting the importance of comorbidities like hypertension or pulmonary disease regarding COVID-19 infection severity in the general population \[[@CR8], [@CR10]--[@CR12]\] but also in series of patients with rheumatic diseases \[[@CR7]\]. We did not find any association between baseline immunosuppressive drugs and hospitalization except for use of glucocorticoids. According to data from 600 patients in the COVID-19 Global Rheumatology Alliance registry showed similar results \[[@CR7]\], most immunosuppressive drugs, including biologics and targeted synthetic agents, were not associated with poorer outcomes. Similar results have been found in a case series of 86 patients with COVID-19 in New York \[[@CR13]\], and in two age and sex-matched control cohorts \[[@CR3], [@CR14]\]. Similarly, Monti et al. \[[@CR15]\], and Conticini et al. \[[@CR6]\] described low incidence of SARS-CoV2 infection in patients with immunosuppressive drugs, suggesting low influence of these medications in acquiring the illness and course severity.

About glucocorticoids influence on COVID-19 evolution, although they could be an alternative therapeutic strategy when distress respiratory syndrome overcome, a possible role in decreasing viral clearance in the initial stage of the disease has been suggested \[[@CR11], [@CR16], [@CR17]\] and may be related to our findings. Uses of glucocorticoids have been associated with a higher risk of hospitalization and severe outcomes also in patients with inflammatory bowel diseases \[[@CR18]\]. Our data are in agreement with other studies and suggest that glucocorticoids early in infection are harmful even though some studies suggest a significant benefit later during the COVID-19 course \[[@CR19]\].

Interestingly, reported data from the COVID-19 Global Rheumatology Alliance registry \[[@CR7]\] showed a lower mortality among rheumatologic patients when comparing with our series. Possible explanations are the lower rate of older patients with only 18% older than 65 in the former series and the lower proportion of hospitalized patients (35% vs 68%). In addition, Madrid was one of the most affected regions by the COVID-19 pandemic in Spain with a considerable rate of severe cases.

Our study has several limitations, as it is a retrospective single-center study, with a small sample and short period study that could limit more conclusive results. Also, a potential selection bias for more severe cases is to be considered. Nevertheless, it is an initial approach to know how COVID-19 infection behave in rheumatic patients and the risk factors associated to a worse prognosis, made in a homogeneous patient group.

In conclusion, age and previous lung disease must be carefully assessed when treating COVID-19 patients with inflammatory and autoimmune rheumatic diseases. More research is needed to evaluate specific immunosuppressive medication and other comorbidity interactions; but according to our data and in agreement with other studies, patients with rheumatic disease do not need to discontinue immunosuppressive drugs. Because of the association of glucocorticoids with poorer outcomes, it is important to minimize exposure.

Results from other studies are expected to further understand the impact of COVID-19 in rheumatologic patients, specially concerning long-term outcomes.
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